Article

Countdown to the Ophthalmology Times Inaugural EyeCon Meeting 2021

Author(s):

Save the dates for this virtual interactive conference featuring top US ophthalmologists

The Ophthalmology Times® Inaugural EyeCon 2021 virtual interactive conference featuring renowned investigators is slated for December 10-11, 2021, and registration is now open. The sessions will run from 8:30 am to 3:55 pm on both days.

Don’t miss this opportunity to access information on the latest insights and advancements in a variety of ophthalmic topics and get CME credits at the same time!

The conference, co-chaired by Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and Texas-based glaucoma specialist Oluwatosin U. Smith, MD, associate professor, Department of Ophthalmology, University of Texas Southwestern, Dallas, will bring together the nation’s top ophthalmology experts to share new data and clinical insight into the most current processes and therapeutics.

Participants will have the opportunity to optimize the use of imaging and other diagnostic tools for earlier identification of ocular diseases, improve team-based interactions with other eye-care specialists and health care providers when treating patients with systemic diseases contributing to vision loss, gain confidence in the use of new and emerging therapies and procedures in the ophthalmology setting, and interact with expert faculty to implement key learnings into practice.

The planned topics to look forward to, according to Drs. McDonnell and Smith, include advances in older topics of interest to ophthalmologist and updates on treatments on the horizon, many of these life-changing. These discussions include investigational and newly approved therapies for geographic atrophy, neovascular age-related macular degeneration, thyroid eye disease, and neuromyelitis optica spectrum disease; sustained drug delivery and minimally invasive glaucoma surgery; advances in cataract and refractive surgery; gene therapy for retinal disease and other ocular conditions; telemedicine during COVID-19; and the latest strategies for managing common concerns, including uveitis, presbyopia, and dry eye disease.

Don’t miss out! Use this link for more information on the conference agenda, faculty, and registration: https://event.gotoper.com/event/a7445a6f-11b7-47c0-a949-e24084b8e45e/summary?_ga=2.66688428.321583691.1633620358-112871981.1624995931

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.